Pharmacological chaperones as therapeutics for lysosomal storage diseases.
Lysosomal enzymes are responsible for the degradation of a wide variety of glycolipids, oligosaccharides, proteins, and glycoproteins. Inherited mutations in the genes that encode these proteins can lead to reduced stability of newly synthesized lysosomal enzymes. While often catalytically competent, the mutated enzymes are unable to efficiently pass the quality control mechanisms of the endoplasmic reticulum, resulting in reduced lysosomal trafficking, substrate accumulation, and cellular dysfunction. Pharmacological chaperones (PCs) are small molecules that bind and stabilize mutant lysosomal enzymes, thereby allowing proper cellular translocation. Such compounds have been shown to increase enzyme activity and reduce substrate burden in a number of preclinical models and clinical studies. In this Perspective, we review several of the lysosomal diseases for which PCs have been studied and the SAR of the various classes of molecules.
Amicus Therapeutics, 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States. rboyd@amicusrx.com
Robert E
RE
Boyd
Gary
G
Lee
Philip
P
Rybczynski
Elfrida R
ER
Benjamin
Richie
R
Khanna
Brandon A
BA
Wustman
Kenneth J
KJ
Valenzano
D002460:Cell Line; D006017:Glycolipids / Q000378:metabolism; D006801:Humans; D016464:Lysosomal Storage Diseases / Q000188:drug therapy*; D018832:Molecular Chaperones / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D006017:Glycolipids; D018832:Molecular Chaperones